In a significant advancement for breast cancer treatment, the FDA has granted approval for ribociclib (marketed as Kisqali) as an adjuvant therapy in combination with endocrine therapy for patients with early high-risk breast cancer. This development marks an important turning point, as ribociclib was previously established for use in metastatic cases. Now, it is officially
Health
Bladder cancer, specifically muscle-invasive bladder cancer (MIBC), has long posed challenges for both patients and healthcare providers alike. Historically, treatment options have relied heavily on neoadjuvant chemotherapy followed by radical cystectomy, but these strategies have led to disappointingly high rates of recurrence and mortality. The recent findings from the NIAGARA trial offer groundbreaking hope that
Squamous cell carcinoma of the anal canal (SCAC) represents a challenging subset of cancers, characterized by its aggressive nature and poor prognosis, particularly in advanced stages. Globally, the incidence of SCAC has been increasing, prompting urgent calls for novel treatment strategies. Current standard therapies primarily involve chemoradiotherapy, though a significant percentage of patients—up to 30%—experience
Menopause signifies a crucial phase in a woman’s life characterized by the cessation of menstruation and a host of hormonal changes. One significant consequence of these changes is the increased prevalence of insulin resistance, a condition where the body fails to respond optimally to insulin. Insulin resistance can set the stage for various metabolic disorders,
The intersection of politics and healthcare remains a heated topic in contemporary discourse, particularly highlighted by former President Donald Trump’s proposal to offer free in vitro fertilization (IVF) treatments. This initiative, while potentially beneficial for many families, has sparked significant outrage among various Republican factions. Critics argue that broad entitlement programs detract from the party’s
The House Energy & Commerce Oversight and Investigations Subcommittee recently held a hearing to address issues within the organ transplant system in the United States. Shocking revelations were made, such as deceased organ donors waking up and asking for help, threats of being “cremated alive” made by organ transplant executives, and organs meant for transplant
The phase III trial of mirtazapine, an inexpensive antidepressant, failed to show any benefit over a placebo in alleviating severe, persisting breathlessness from chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The study’s primary outcome, “worst breathlessness” over the past 24 hours, as measured on a 0-10 numeric rating scale, showed no significant
Recent research has indicated that CAR T-cell therapy does not pose a higher risk of second primary malignancies (SPM) compared to other standard-of-care cancer therapies. In a systematic literature review and meta-analysis, a total of 5,517 patients were examined, showing a 5.8% rate of SPM with a median follow-up of 21.7 months. Interestingly, the study
Obesity in young children has become a growing concern, with many struggling to achieve a healthy weight through lifestyle interventions alone. However, a recent phase IIIa trial called SCALE Kids has shed light on a potential solution involving the use of liraglutide (Saxenda) in combination with lifestyle changes. The trial, led by Claudia Fox, MD,
The analysis of two phase III trials examining the efficacy of perioperative nivolumab in non-small cell lung cancer (NSCLC) patients shows promising results in reducing the risk of disease recurrence or death post-surgery. The study compared patients who received neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab versus patients who did not receive